2019 Volume 45 Issue 3 Pages 294-299
Background: The EXTREME regimen is the most established standard treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma.
Methods: We retrospectively reviewed R/M HNSCC patients who were treated with the EXTREME regimen in our institution from February 2013 to October 2015. The EXTREME regimen consists of cisplatin or carboplatin on day 1, continuous 5-FU on days 1 to 4, and cetuximab on days 1, 8, and 15, for every 3 weeks, the same as the original article. The response rate （RR）, progression-free survival （PFS）, overall survival （OS）, and adverse events （AE） were evaluated.
Results: A total of 34 patients were enrolled. Partial response rate was 50％, and there was no complete response. The median PFS was 5.1 months, and the median OS was 15.9 months. The most common grade 3 AEs were neutropenia, leukopenia, anorexia, and hyponatremia.
Conclusions: In our institute, the EXTREME regimen is a safe and effective treatment for R/M HNSCC patients.
